scholarly journals A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients

2014 ◽  
Vol 168 (2) ◽  
pp. 219-229 ◽  
Author(s):  
M. Mansour Ceesay ◽  
Sujal R. Desai ◽  
Lisa Berry ◽  
Joanne Cleverley ◽  
Christopher C. Kibbler ◽  
...  
Keyword(s):  
At Risk ◽  
Computerized Tomography ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Diagnostic Approach ◽  
Significant Burden ◽  
Haematology Patients

scholarly journals Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

2017 ◽  
Vol 72 (12) ◽  
pp. 3501-3501 ◽  
Author(s):  
Oliver A Cornely ◽  
Michael N Robertson ◽  
Shariq Haider ◽  
Andrew Grigg ◽  
Michelle Geddes ◽  
...  
Keyword(s):  
At Risk ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Patients At Risk

scholarly journals Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

2017 ◽  
Vol 72 (12) ◽  
pp. 3406-3413 ◽  
Author(s):  
Oliver A Cornely ◽  
Michael N Robertson ◽  
Shariq Haider ◽  
Andrew Grigg ◽  
Michelle Geddes ◽  
...  
Keyword(s):  
At Risk ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Patients At Risk

scholarly journals Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome

2016 ◽  
Vol 54 (7) ◽  
pp. 691-698 ◽  
Author(s):  
M. Mansour Ceesay ◽  
Lewis Couchman ◽  
Melvyn Smith ◽  
Jim Wade ◽  
Robert J. Flanagan ◽  
...  
Keyword(s):  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Serum Concentrations ◽  
Trough Serum ◽  
Haematology Patients

scholarly journals Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

2015 ◽  
Vol 71 (3) ◽  
pp. 718-726 ◽  
Author(s):  
Oliver A. Cornely ◽  
Rafael F. Duarte ◽  
Shariq Haider ◽  
Pranatharthi Chandrasekar ◽  
David Helfgott ◽  
...  
Keyword(s):  
At Risk ◽  
Steady State ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Oral Suspension ◽  
Safety Study ◽  
Phase 3 ◽  
Once Daily ◽  
Patients At Risk ◽  
Phase 1B

This Phase 1B study showed that a single tablet of 300 mg of posaconazole, given once daily as prophylaxis to 210 patients at risk for invasive fungal disease, was as safe as that reported for posaconazole oral suspension and achieved steady-state >500 ng/mL for all but one patient.

scholarly journals Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients

Mycoses ◽  
2018 ◽  
Vol 61 (9) ◽  
pp. 623-632 ◽  
Author(s):  
Helena Hammarström ◽  
Anna Stjärne Aspelund ◽  
Bertil Christensson ◽  
Claus Peter Heußel ◽  
Jenny Isaksson ◽  
...  
Keyword(s):  
High Risk ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Prospective Evaluation ◽  
Haematology Patients ◽  
Fungal Biomarkers

scholarly journals Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

2016 ◽  
Vol 71 (6) ◽  
pp. 1747-1747 ◽  
Author(s):  
Oliver A. Cornely ◽  
Rafael F. Duarte ◽  
Shariq Haider ◽  
Pranatharthi Chandrasekar ◽  
David Helfgott ◽  
...  
Keyword(s):  
At Risk ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Tablet Formulation ◽  
Safety Study ◽  
Phase 3 ◽  
Patients At Risk

scholarly journals Triggers for driving treatment of at-risk patients with invasive fungal disease

2013 ◽  
Vol 68 (suppl 3) ◽  
pp. iii17-iii24 ◽  
Author(s):  
L. Drgona ◽  
A. Colita ◽  
N. Klimko ◽  
G. Rahav ◽  
M. A. Ozcan ◽  
...  
Keyword(s):  
At Risk ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Risk Patients

scholarly journals Lessons from an Educational Invasive Fungal Disease Conference on Hospital Antifungal Stewardship Practices across the UK and Ireland

2021 ◽  
Vol 7 (10) ◽  
pp. 801
Author(s):  
Alida Fe Talento ◽  
Malcolm Qualie ◽  
Laura Cottom ◽  
Matthijs Backx ◽  
P. Lewis White
Keyword(s):  
At Risk ◽  
Treatment Strategies ◽  
Invasive Fungal Disease ◽  
Fungal Disease ◽  
Diagnostic Tools ◽  
Optimal Time ◽  
Rapid Diagnostics ◽  
Antifungal Stewardship ◽  
Patients At Risk ◽  
The Uk

Invasive fungal disease (IFD) is a growing health burden. High mortality rates, increasing numbers of at-risk hosts, and a limited availability of rapid diagnostics and therapeutic options mean that patients are increasingly exposed to unnecessary antifungals. High rates of prescriptions promote patient exposure to undue toxicity and drive the emergence of resistance. Antifungal stewardship (AFS) aims to guide antifungal usage and reduce unnecessary exposure and antifungal consumption whilst maintaining or improving outcomes. Here, we examine several AFS approaches from hospitals across the UK and Ireland to demonstrate the benefits of AFS practices and support the broader implementation of AFS as both a necessary and achievable strategy. Since the accuracy and turnaround times (TATs) of diagnostic tools can impact treatment decisions, several AFS strategies have included the development and implementation of diagnostic-driven care pathways. AFS informed treatment strategies can help stratify patients on a risk basis ensuring the right patients receive antifungals at the optimal time. Using a multidisciplinary approach is also key due to the complexity of managing and treating patients at risk of IFD. Through knowledge sharing, such as The Gilead Antifungal Information Network (GAIN), we hope to drive practices that improve patient management and support the preservation of antifungals for future use.

Sign in / Sign up

Export Citation Format

Share Document